Physician profile
Marshall Wise
NPI 1427105394
$5,997.59
in general payments reported to CMS, 2019-2025
23 companies · $948 in 2025
The $948 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $466 · 2021: $971 · 2022: $831 · 2023: $1,110 · 2024: $1,329 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,277.30 |
| Education | $110.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,387.18 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,151.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $703.86 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Optinose US, INC. | $512.65 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $389.13 | 2022-2025 | |
| Blueprint Medicines Corporation | $278.91 | 2022-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $220.35 | 2022-2025 | Dupixent |
| Genentech USA, INC. | $182.89 | 2022-2024 | Xolair |
| Csl Behring | $164.82 | 2019-2023 | Haegarda |
| Biocryst US Sales Co., LLC | $140.23 | 2021-2023 | Orladeyo |
| Pfizer INC. | $134.54 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.53 | 2020-2021 | |
| Amgen INC. | $132.83 | 2021-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $94.99 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $81.58 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $81.21 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.41 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $43.89 | 2025 | Neffy |
| Mylan Specialty L.P. | $28.07 | 2021 | |
| Aimmune Therapeutics, INC. | $25.51 | 2021 | |
| Kaleo, INC. | $18.60 | 2022 | |
| Leo Pharma INC. | $18.33 | 2023 | Adbry |
| Octapharma USA, INC. | $17.48 | 2024 | Panzyga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Wise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.